CD8A and neoplasm: A recent study showed that bevacizumab could not only suppress angiogenesis but also inhibit VEGF-mediated regulatory T cell (Treg) proliferation and myeloid cell inflammation and work synergistically with atezolizumab to increase the proportion of CD8 + T cells and dendritic cells in TME, thereby activating anti-tumor immunity and hampering tumor growth [48].